呼吸道合胞病毒感染动物模型的构建与评价  

Construction and evaluation of animal models of respiratory syncytial virus infection

作　　者：齐莉莉[1] 刘宏[2] 李剑[3] QI Lili;LIU Hong;LI Jian(Teaching Experiment Center of Hebei Medical University,Shijiazhuang 050017,China;the Second Hospital of Hebei Medical University,Shijiazhuang 050000;Basic Medicine College of Hebei Medical University,Shijiazhuang 050017)

机构地区：[1]河北医科大学教学实验中心,石家庄050017 [2]河北医科大学第二医院,石家庄050000 [3]河北医科大学基础医学院,石家庄050017

出　　处：《中国实验动物学报》2022年第7期989-995,共7页Acta Laboratorium Animalis Scientia Sinica

基　　金：河北省自然科学基金(C2021206004);河北省高等学校科学技术研究项目(QN2021098);河北省中医药管理局科研计划项目(2021118);河北省大学生创新性实验计划项目(CXSY2020002);河北医科大学“春雨计划”项目(CYCZ2021002)。

摘　　要：人类呼吸道合胞病毒(human respiratory syncytial virus,hRSV)是在世界范围内引起呼吸道疾病和婴儿住院的主要原因。目前尚无有效的hRSV疫苗或治疗药物。针对hRSV易感人群的候选疫苗已经处于开发阶段,因此hRSV的动物模型在hRSV候选疫苗的临床前试验中发挥着重要作用。尽管许多模型在临床前研究中显示了有效性,但很少有模型进入临床试验,或者它们的成功率较低。这在一定程度上是由于缺乏完全重现人类hRSV感染发病机制的动物模型。本文分析了hRSV动物模型的优点和局限性,包括用hRSV感染非人类哺乳动物宿主,以及非人类肺病毒动物模型的研究进展,以期为hRSV感染动物模型的合理构建提供思路。Human respiratory syncytial virus(hRSV)is a major cause of respiratory disease and infant hospitalization worldwide.At present,there is no effective hRSV vaccine or therapeutic drug.A candidate vaccine for the hRSV susceptible population is currently being developed,and an animal model of hRSV would therefore play an important role in the preclinical trials of a hRSV candidate vaccine.Although many models have shown effectiveness in preclinical studies,few have entered clinical trials and their success rate has been low.Animal models to date have been unable to fully reproduce the pathogenesis of hRSV infection.Here,we analyze the advantages and limitations of hRSV animal models,including the use of hRSV to infect non-human mammalian hosts and the development of non-human pulmonary virus animal models.The aim of this review is to provide a rational strategy for the construction of an effective animal model of hRSV infection.

关 键 词：呼吸道合胞病毒 动物模型 疫苗 肺损伤 

分 类 号：Q95-33[生物学—动物学]